Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Theratechnologies Inc. THTX
$0.93
-$0.01 (-0.75%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
96806304.00000000
-
week52high
2.77
-
week52low
0.70
-
Revenue
80057000
-
P/E TTM
-2
-
Beta
1.61784600
-
EPS
-0.48000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 июл 2023 г. в 12:30
Описание компании
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Hold | Buy | 29 июл 2021 г. |
| Canaccord Genuity | Buy | Buy | 19 апр 2021 г. |
| Canaccord Genuity | Buy | Buy | 15 апр 2020 г. |
| Mackie Research | Buy | Hold | 11 дек 2019 г. |
| Cantor Fitzgerald | Overweight | 17 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Theratechnologies Inc. (THTX) Q3 2022 Earnings Call Transcript
Seeking Alpha
13 окт 2022 г. в 11:38
Theratechnologies Inc. (NASDAQ:THTX ) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais - Chief Medical Officer John Leasure - Global Commercial Officer Conference Call Participants Andre Uddin - Research Capital Endri Leno - National Bank Doug Loe - Leede Jones Gable Operator Good morning ladies and gentlemen and thank you for standing by. Welcome to Theratechnologies' Third Quarter Fiscal Year 2022 Earnings Call.
Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
GlobeNewsWire
26 сент 2022 г. в 07:30
MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022.
Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
GlobeNewsWire
19 сент 2022 г. в 16:15
MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City. The presentation is available only to attendees of the conference: https://www.cantor.com/cantor-oncology-hemonc-conference/
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
GlobeNewsWire
02 авг 2022 г. в 07:30
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1:00 p.m. ET.
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
14 июл 2022 г. в 13:42
Theratechnologies Inc. (NASDAQ:THTX ) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET Company Participants Elif McDonald - Senior Director, Investor Relations Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer John Mullaly - IR, LifeSci Advisors Conference Call Participants Edward Nash - Canaccord Genuity Andre Uddin - Research Capital Endri Leno - National Bank Operator Good morning and welcome to the Theratechnologies' Second Quarter Fiscal Year 2022 Earnings Call. [Operator Instructions].